First evidence of the conversion of paracetamol to AM404 in human cerebrospinal fluid

Chhaya V Sharma,1 Jamie H Long,2 Seema Shah,1 Junia Rahman,1 David Perrett,3 Samir S Ayoub,4 Vivek Mehta1
1Pain & Anaesthesia Research Centre, St Bartholomew’s and The Royal London Hospitals, Barts Health NHS Trust, London, UK; 2Barts & The London School of Medicine, Queen Mary University of London, London, UK; 3BioAnalytical Science, Barts & The London School of Medicine, Queen Mary University of London, London, UK; 4School of Health, Sport and Bioscience, Medicines Research Group, University of East London, London, UK

Abstract: Paracetamol is arguably the most commonly used analgesic and antipyretic drug worldwide, however its mechanism of action is still not fully established. It has been shown to exert effects through multiple pathways, some actions suggested to be mediated via N-arachidonoylphenolamine (AM404). AM404, formed through conjugation of paracetamol-derived p-aminophenol with arachidonic acid in the brain, is an activator of the capsaicin receptor, TRPV1, and inhibits the reuptake of the endocannabinoid, anandamide, as well as inhibiting synthesis of PGE2 by COX-2. However, the presence of AM404 in the central nervous system following administration of paracetamol has not yet been demonstrated in humans. Cerebrospinal fluid (CSF) and blood were collected from 26 adult male patients between 10 and 211 minutes following intravenous administration of 1 g of paracetamol. Paracetamol was measured by high-performance liquid chromatography with UV detection. AM404 was measured by liquid chromatography-tandem mass spectrometry. AM404 was detected in 17 of the 26 evaluable CSF samples at 5–40 nmol L⁻¹. Paracetamol was measurable in CSF within 10 minutes, with a maximum measured concentration of 60 μmol L⁻¹ at 206 minutes. This study is the first to report on the presence of AM404 in human CSF following paracetamol administration. This may represent an important finding in our understanding of paracetamol’s mechanism of action, although measured concentrations were far below the previously documented IC50 for this metabolite.

Keywords: acetaminophen, paracetamol, paracetamol: mechanism of action, AM404, N-arachidonoylphenolamine, pharmacology - theories of analgesic action

Introduction

Despite its discovery over a century ago and ubiquitous clinical use, the mechanism of action of paracetamol remains undetermined, although involvement of multiple central pathways has been demonstrated. These include effects on prostaglandin production,1,2 on serotonergic pathways,3,4 and more recently, there has been increasing evidence for the roles of the endocannabinoid system and TRPV1 receptor in paracetamol’s antinociceptive (though not its hypothermic) effects.5–8

Arachidonoyl ethanolamine (AEA, anandamide) is an endogenous cannabinoid present in the human nervous system, with demonstrated antinociceptive actions. Its actions are terminated by a two-step inactivation process beginning with its reuptake from the synaptic cleft into the postsynaptic neuron by a recently characterized FAAH-like anandamide transporter (FLAT).9 Inside the neuron, AEA is hydrolyzed by the enzyme FAAH. Paracetamol has been suggested to exert its analgesic actions by interfering with the reuptake of AEA by using FAAH to form a novel metabolite...
N-arachidonoylphenolamine (AM404) through conjugation in brain tissue of paracetamol-derived para-aminophenol with arachidonic acid. The consequence of this is increased AEA within the synaptic cleft, producing increased cannabinoid receptor (CB1) activation. AM404 is also an activator of TRPV1, otherwise known as the capsaicin receptor.

Although the potential central antinociceptive role of AM404 has been investigated in animal models, its role in humans is not clear. AM404 has been found only as a metabolite of paracetamol and is not an endogenous component of human or animal nervous systems. However, its presence in cerebrospinal fluid (CSF) following paracetamol administration in humans has not been reported. The purpose of this pilot study was to investigate whether AM404 is present in human CSF following a single intravenous dose of paracetamol.

**Methods**

**Study design and patient randomization**

Following approval by the East London Research Ethics Committee (ref: 2010-019488-12), EudraCT registration (ref: 2010-019488-12), and receipt of written informed consent from all participants, 30 American Society of Anesthesiology classification of perioperative risk of anesthesia I–III adult male and female patients, aged between 18 and 80 years, were recruited to the study. These patients were scheduled to undergo elective urological surgery under spinal anesthesia. Exclusion criteria were any contraindication to spinal anesthesia, known hypersensitivity to paracetamol or severe hepatocellular insufficiency, patients taking paracetamol in the preceding 12 hours, or pregnancy or lactation in women. Patients were given a single intravenous dose of 1 g paracetamol (100 mL solution, Perfalgan; Bristol-Myers Squibb Pharmaceutical Limited, Middlesex, UK) as an infusion over 10 minutes, and were randomized for sample collection at 15, 30, or 120 minutes post-infusion, prior to their spinal anesthetic (administration to sampling interval). At the time of the lumbar puncture but before injection of intrathecal local anesthetic agents, CSF (5 mL) and blood (10 mL) samples were collected.

Randomization was achieved using sealed envelopes containing the study group allocation (for sampling at 15, 30, or 120 minutes post-paracetamol administration). The sealed envelope was selected by a member of the research team not involved in data collection or analysis. As outcomes of the study were measured values of paracetamol and its metabolite, AM404, rather than subjective patient experience, clinical bias was not a concern and masking was not carried out.

**Sample collection and storage**

CSF and blood sample were collected into EDTA tubes, stored on ice, centrifuged at 1,400×g at 4°C for 15 minutes, and then frozen at −20°C until analysis.

**Materials**

Paracetamol reference samples were from Sigma-Aldrich Co. (St Louis, MO, USA); AM404 and palmitoylthanolamide-d4 (PEA-d4) were from Cayman Chemicals (Ann Arbor, MI, USA); ammonium acetate, potassium phosphate, and EDTA were from VWR (Lutterworth, UK). Analytical grade methanol, acetonitrile, H2O, and formic acid were from Fisher Scientific UK Ltd (Loughborough, UK).

**Measurement of paracetamol in CSF and plasma**

High-performance liquid chromatography (HPLC) analysis was performed on a Jasco system. CSF (100 μL) was diluted with 100 μL 50 mM ammonium acetate, pH 5.5, containing 183 nmol.mL−1 3-aminophenol (internal standard). One hundred microliters of plasma was precipitated with 300 μL acetonitrile containing 183 nmol.mL−1 3-aminophenol. Extracted plasma was centrifuged at 13,000×g for 10 minutes and 100 μL supernatant was diluted with 100 μL 50 mM potassium phosphate, pH 6.5. Extracts were injected (20 μL for CSF, 10 μL for plasma) and separated on a Thermo Scientific C18 column (100 × 4.6 mm, 5 μm). For CSF, elution was carried out with 50 mM ammonium acetate (pH 5.5) containing 1 mM EDTA and 5% methanol. For plasma, 50 mM potassium phosphate (pH 6.5) containing 1 mM EDTA and 5% methanol was used. The column was eluted at 1 mL.min−1 using a Jasco PU-980 pump. Detection was at 242 nm using a Jasco UV-975 detector. The retention time for paracetamol was 7.05 minutes and that of the internal standard was 3.5 minutes. The HPLC for paracetamol was calibrated to a six-point curve of 0–1.65 mmol L−1. The matrix was PBS for CSF and paracetamol-free human plasma for plasma samples. The limit of detection for paracetamol in CSF and plasma were 54 nmol L−1 and 200 nmol L−1, respectively (S/N=3). The limits of quantitation for paracetamol in CSF and plasma were 180 nmol L−1 and 600 nmol L−1, respectively (S/N=10).

**Measurement of AM404 in CSF and plasma**

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed on a Thermo Scientific Accela system attached to a TSQ Vantage mass spectrometer. One hundred microliters of CSF was diluted with
One hundred microliters of plasma was precipitated with 300 μL acetonitrile containing 329 nmol/L internal standard PEA-d4. Extracts (10 μL) were injected onto a Waters Acquity BEH phenyl column (2.1 x 50 mm, 1.7 μm), maintained at 50°C, and eluted at 0.5 mL min⁻¹. Initially, the eluent was 95% aqueous, 0.1% formic acid, 5% methanol, increasing linearly over 3 minutes to 95% methanol, 5% aqueous, 0.1% formic acid. This was held for 2 minutes and then returned to initial conditions to re-equilibrate. Positive electrospray ionization was used, with an ion spray voltage of 3,500 V and no declustering voltage applied. AM404 was detected by monitoring the 396.3/110.2 m/z transition using a collision energy of 9 V. The detection time for AM404 was 4.25 minutes. LC-MS/MS for AM404 was calibrated to an eight-point curve 0–300 μmol L⁻¹. The limits of detection of AM404 in CSF and plasma were 0.1 nmol L⁻¹ and 1.6 nmol L⁻¹, respectively (S/N=3). The limits of quantitation for AM404 in CSF and plasma were 0.5 nmol L⁻¹ and 5 nmol L⁻¹, respectively (S/N=10). The LC-MS/MS parameters were set as follows: collision gas was argon, spray voltage was 3,500 V, vaporizer temperature was 300°C, sheath gas pressure was 60 psi, capillary temperature was 270°C, collision cell pressure was 1.5 mTorr, and no declustering voltage was applied. Full details of the analytical methodologies are in Long.14

## Results

### Patient recruitment

Of the 30 patients recruited, only three were female. Additionally, two of the patients, one male and one female, were later found to have taken an additional dose of paracetamol in the previous 12 hours, violating exclusion criteria. Data from these four patients were therefore excluded from analysis, such that results from 26 male patients were analyzed in total (Table 1).

As expected, given the unpredictable nature of the operating theater lists, it was not possible to collect samples precisely at the intended time points. CSF samples were collected over a range of 10–206 minutes and blood over...
15–211 minutes. The mean CSF-blood collection interval was 4.9 minutes, ranging 0–10 minutes (Table 1).

**CSF and plasma sample analyses**

Following intravenous administration, paracetamol and AM404 were measured in CSF and plasma (Table 2). Paracetamol was detectable in CSF at 10 minutes at 5 μmol·L⁻¹, and at a maximal measured concentration of 99 μmol·L⁻¹. In plasma, the paracetamol concentration ranged from 92 to 506 μmol·L⁻¹ (Table 2).

AM404 was detected in 17 of the 26 evaluable CSF samples from 10 minutes post-administration; 14 of these were above the level of reliable quantitation of 5 nmol·L⁻¹, ranging mostly from 5.1 to 57.4 nmol·L⁻¹ with one anomalous measurement of 166.8 nmol·L⁻¹. Measured AM404 concentrations in CSF did not correlate with time of collection (Figure 2). AM404 was detectable in only eight of the 26 plasma samples, with three being above the limit of quantitation (>5 nmol·L⁻¹), ranging from 6.1 to 65.4 nmol·L⁻¹.

**Table 2** Paracetamol and AM404 concentrations in plasma and CSF at various time intervals following intravenous administration of 1 g of paracetamol in 26 male patients

<table>
<thead>
<tr>
<th>Plasma</th>
<th>CSF</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sample time (minutes)</strong></td>
<td><strong>Paracetamol (μmol L⁻¹)</strong></td>
</tr>
<tr>
<td>15</td>
<td>441</td>
</tr>
<tr>
<td>17</td>
<td>286</td>
</tr>
<tr>
<td>18</td>
<td>256</td>
</tr>
<tr>
<td>21</td>
<td>417</td>
</tr>
<tr>
<td>25</td>
<td>402</td>
</tr>
<tr>
<td>25</td>
<td>271</td>
</tr>
<tr>
<td>27</td>
<td>351</td>
</tr>
<tr>
<td>27</td>
<td>289</td>
</tr>
<tr>
<td>28</td>
<td>319</td>
</tr>
<tr>
<td>29</td>
<td>351</td>
</tr>
<tr>
<td>35</td>
<td>506</td>
</tr>
<tr>
<td>38</td>
<td>341</td>
</tr>
<tr>
<td>40</td>
<td>213</td>
</tr>
<tr>
<td>42</td>
<td>265</td>
</tr>
<tr>
<td>46</td>
<td>216</td>
</tr>
<tr>
<td>57</td>
<td>188</td>
</tr>
<tr>
<td>62</td>
<td>167</td>
</tr>
<tr>
<td>73</td>
<td>410</td>
</tr>
<tr>
<td>74</td>
<td>168</td>
</tr>
<tr>
<td>85</td>
<td>206</td>
</tr>
<tr>
<td>85</td>
<td>191</td>
</tr>
<tr>
<td>87</td>
<td>247</td>
</tr>
<tr>
<td>121</td>
<td>118</td>
</tr>
<tr>
<td>134</td>
<td>150</td>
</tr>
<tr>
<td>150</td>
<td>92</td>
</tr>
<tr>
<td>211</td>
<td>130</td>
</tr>
</tbody>
</table>

**Discussion**

Evidence for a pharmacological function of paracetamol-derived AM404 in rodents has been previously documented; however, there is no evidence of a similar metabolic pathway in human tissues. The current study is the first to report on the presence of AM404 in human CSF and plasma samples following intravenous administration of 1 g paracetamol.

AM404, a putatively active metabolite of paracetamol and apparent intermediary in several analgesic pathways in animal models, was measured in CSF in 14 of 26 patients at concentrations of 5.1–57.4 nmol·L⁻¹ with an outlier at 166.8 nmol·L⁻¹; it was also detectable in a further three human CSF samples below the level of reliable quantitation (<5 nmol·L⁻¹). AM404 was not detected in plasma in the majority of subjects in this study, consistent with findings of Högestätt et al, who reported on the absence of AM404 in rat plasma. In the present study, AM404 above 5 nmol·L⁻¹ was, however, found in the plasma of three of the 26 patients (range: 6.1–65.4 nmol·L⁻¹). This finding warrants further investigation and identification of the metabolic pathways involved in the formation of AM404 in human plasma.
investigation as there would appear to be a mechanism through which AM404 leaks out of the brain and into blood, but is only functional in some individuals.

Although this study reports the presence of AM404 in human CSF, the exact pathway and clinical relevance in humans remain unclear, as the evidence to date on AM404 comes largely from animal studies. AM404 has been demonstrated in in vitro studies to inhibit reuptake of anandamide, $^{9,10,15,16}$ TRPV1 receptor activity, $^{10,11}$ and PGE$_2$ production via COX-1 and COX-2, $^{10}$ in the high nanomolar to low micromolar concentration range. Ex vivo animal studies have detected levels of AM404 in whole brain tissue equating to the low nanomolar range following systemic administration of standard analgesic doses of paracetamol in rats.
Using the hot plate test of acute nociception, it was found that AM404 at a dose of 10 mg kg⁻¹ potentiated the analgesic action of anandamide. Additionally, it was shown that 1–10 mg kg⁻¹ attenuated the formalin-induced chronic constriction injury models of acute and chronic pain, respectively, in a CB₁ receptor-dependent manner.

In the present study, nanomolar concentrations of AM404 were measured in human CSF samples taken from low level lumbar puncture. As FAAH is mostly expressed in discrete areas of brain tissue, it is hypothesized that AM404 would be formed predominantly in the brain following administration of paracetamol, from where it diffuses into CSF. Ex vivo rat studies support this, with the majority of AM404 (following paracetamol administration) being found in brain tissue, to a lesser extent in the spinal cord (15-fold less), and negligible amounts in plasma. It is likely, therefore, that human CSF concentrations of AM404 (surrogate measures of brain concentration) significantly underestimate the concentration in areas of the brain rich in FAAH. Levels measured in this study may therefore correspond to much greater amounts formed in human brain following paracetamol administration.

Several investigations aimed at elucidating the pharmacological mechanism of action of paracetamol have reported on paracetamol-derived AM404 playing a key role in mediating the analgesic action of paracetamol in rodents. Mallet et al demonstrated that inhibition of brain FAAH activity, thereby preventing the conversion of paracetamol into AM404, suppressed the analgesic action of paracetamol in animal models of thermal, mechanical, and chemical pain. The authors also propose that AM404 mediates these analgesic actions through activation of CB₁ receptor and 5-HT descending inhibitory pathway. These findings have been extended to also propose involvement of TRPV1 as an analgesic target for paracetamol in rats at doses of paracetamol similar to therapeutic doses in humans. However, the authors report on a conversion rate of paracetamol to AM404 of only 0.0013% with claims of analgesic significance, which has not been demonstrated. Using pharmacological and genetic approaches to abolish the expression or function of FAAH to prevent the synthesis of AM404, it was demonstrated that the hypothermic action of paracetamol was similar to control mice and that the observed paracetamol-induced hypothermia was not dependent on cannabinoids or TRPV1.

Historical as well as somewhat recent investigations on the mechanism of action of paracetamol have focused on direct or indirect inhibition of the activity of the COX enzymes as the target for the analgesic action of paracetamol. These in vitro and in vivo experiments consistently demonstrated reduction of brain and spinal cord prostaglandin synthesis, which is likely to be an action either directly of paracetamol or through AM404.

This study does not report on the pharmacokinetic modeling of paracetamol, which has been previously well-documented. A study by Kumpulainen et al on the CSF pharmacokinetics of paracetamol in children, using serial sampling following a 15 mg kg⁻¹ intravenous dose, showed paracetamol to be rapidly detectable, within 5 minutes, and reaching a maximum concentration equivalent to 119 μmol L⁻¹ at 57 minutes. Another study, by Singla et al, on plasma and CSF pharmacokinetics following intravenous paracetamol in healthy adults reports a CSF Cmax of 39 μmol L⁻¹ at 2 hours. These figures corroborate our findings that paracetamol rapidly enters the CSF following intravenous administration, detectable as early as 10 minutes in the low μmol L⁻¹ range (Figure 1).

Although this study reports the presence of AM404 in human CSF, the extent of its clinical relevance remains unclear. The IC₅₀ of AM404 for AEA uptake or EC₅₀ for TRPV1 activation have not been measured in human CSF, though in rat neural tissue, the IC₅₀ for AEA uptake has been found to be ~5 μmol L⁻¹. In the present study, concentrations ranging 5.1–57.4 nmol L⁻¹ with an outlier at 166.8 nmol L⁻¹ were measured. However, as mentioned previously, it is possible that these low concentrations of AM404 in CSF correspond to much higher levels in FAAH-rich areas of the brain.

Further to the identification of a potential central antinociceptive role of AM404 in animal models, its presence in CSF in humans following paracetamol administration is a significant finding, reported here for the first time. Whilst this represents a potentially important step in furthering our understanding of paracetamol’s mechanism(s) of action, given the extremely low levels of AM404 detected in the CSF, its role in the clinical actions of paracetamol requires further investigation.

Acknowledgment
This paper was presented as an abstract and poster at the 31st Annual Scientific Meeting of the American Pain Society, Honolulu, Hawaii, May 16–19, 2012.

Disclosure
The authors report no conflicts of interest in this work.
References


